Eurofins Discovery announces their latest publication, SH2scan: Mapping SH2 Domain-Ligand Binding Selectivity for Inhibitors and Degraders, on the cover of the Journal of Medicinal Chemistry showcasing SH2scan, a high-throughput assay platform that profiles SH2 domain-ligand interactions across >80% of canonical SH2 domains.

An industry-leading provider of products and services for drug discovery announced today a publication in ACS Pharmacology & Translational Science Journal

Eurofins Discovery proudly celebrates its innovators of 2024, recognizing outstanding Eurofins Discovery teams for their exceptional contributions to scientific technology and business innovation.

The expansion of its chemistry services offering, designed to accelerate discoveries, enhance project success, and bring clients’ greater proximity, responsiveness, and control.

Eurofins Discovery, an industry-leading provider of products and services for drug discovery announced today a latest publication in ACS Pharmacology & Translational Science Journal, titled “Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-Covalent Mechanisms.“

The current tariff environment is highly volatile, and we understand this is a period of significant uncertainty. While we are diligently assessing the possible impact on our supply chain, Eurofins Discovery is committed to ensuring no to minimal disruption in our services.